In vitro and animal model studies have shown erythropoietin receptor (Epo-R) mRNA and/or
protein may be present in a range of human tumours and cancer cell lines, and …

Safety concerns surrounding the use of recombinant human erythropoietin (Epo) to treat
anemia in cancer patients were raised after 2 recent clinical studies reported a worse …

Given the apparent presence of erythropoietin receptors (EPORs) in cancer tissues,
questions have been raised about the possible influence of erythropoiesis-stimulating …

Recombinant human erythropoietin (rhEPO) has been used clinically to alleviate cancer-and
chemotherapy-related anemia. However, recent clinical trials have reported that rhEPO also …

Erythropoietin (EPO) is the primary regulator of erythropoiesis, and promotes the survival,
proliferation, and differentiation of erythroid progenitor cells. The EPO receptor belongs to …

Erythropoietin (Epo) therapy reduces red cell transfusion requirements and improves the
quality of life of anemic cancer patients receiving chemotherapy. However, there is concern …

Abstract Purpose: Erythropoietin (EPO) and EPO receptor (EPO-R) expression have been
reported in solid tumors and are claimed to regulate tumor growth; however, no data have …

Erythropoietin (Epo) is an essential hormone that binds and activates the Epo receptor
(EpoR) resident on the surface of erythroid progenitor cells, thereby promoting …

The identification of erythropoietin receptors (EpoR) on cancer cells has caused concern,
since it implies the possibility that treatment of cancer patients with erythropoietin (Epo) and …

The hormone erythropoietin (EPO) is essential for the survival, proliferation and
differentiation of the erythrocytic progenitors. The EPO receptor (EPO-R) of erythrocytic cells …